Jonathan Violin

CIK: 0001730615

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (83.3%)

Compensation grants

Other (G, F, J, C, D, …)1 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

KRSA

Korsana Biosciences, Inc.

DirectorOfficer

CBIO

CRESCENT BIOPHARMA, INC.

Director

DNTH

Dianthus Therapeutics, Inc. /DE/

Director

ATXS

Astria Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

CBIO
CRESCENT BIOPHARMA, INC.
Jun 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
11.1K shares-
DNTH
Dianthus Therapeutics, Inc. /DE/
May 21, 2026
Award(A)
Stock Option (Right to Buy)
Direct
6.1K shares-
ATXS
Astria Therapeutics, Inc.
Jan 23, 2026
Disposition(D)
Direct
263.3K shares-
CBIO
GLYCOMIMETICS INC
Jun 23, 2025
Award(A)
Stock Option (Right to Buy)
Direct
9K shares-
ATXS
Astria Therapeutics, Inc.
Jun 11, 2025
Award(A)
Stock Option (Right to Buy)
Direct
26.6K shares-
DNTH
Dianthus Therapeutics, Inc. /DE/
May 22, 2025
Award(A)
Stock Option (Right to Buy)
Direct
12.5K shares-

		Type	Shares	Price		Ownership
Jun 2, 2026	CBIO CRESCENT BIOPHARMA, INC.	Award(A) Stock Option (Right to Buy)	11,050	-	-	Direct
May 21, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	6,090	-	-	Direct
Jan 23, 2026	ATXS Astria Therapeutics, Inc.	Disposition(D)	263,321	-	$0	Direct
Jun 23, 2025	CBIO GLYCOMIMETICS INC	Award(A) Stock Option (Right to Buy)	9,023	-	-	Direct
Jun 11, 2025	ATXS Astria Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	26,550	-	-	Direct
May 22, 2025	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	12,500	-	-	Direct

1-6 of 6 transactions

About Violin Jonathan

Violin Jonathan (SEC CIK 0001730615) files insider reports with the SEC as Director of Korsana Biosciences, Inc. (KRSA), Director of CRESCENT BIOPHARMA, INC. (CBIO) and Director of Dianthus Therapeutics, Inc. /DE/ (DNTH). Signal8 also holds filings tied to 1 other company.

Signal8 holds 8 ownership filings by Violin Jonathan (2 Form 3, 6 Form 4), filed between May 22, 2025 and Sep 10, 2026. Those filings report 6 transactions, from May 22, 2025 to Jun 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Violin Jonathan's filings is in WALTHAM, MA.

Recent filings by Violin Jonathan

Jun 2, 2026: Grant or award of CBIO derivative securities (Form 4, code A).
May 21, 2026: Grant or award of DNTH derivative securities (Form 4, code A).
Jan 23, 2026: Disposition to issuer transaction of ATXS shares (Form 4, code D).
Jun 23, 2025: Grant or award of CBIO derivative securities (Form 4, code A).
Jun 11, 2025: Grant or award of ATXS derivative securities (Form 4, code A).

Other insiders filing for Korsana Biosciences, Inc. (KRSA)

Pernice Michelle Patricia, Director
Shah Nimish P, Director
Fairmount Funds Management LLC, Director
Gottesdiener Andrew, Director
Leoni Matthew James, Chief Medical Officer
HENSON HEIDI, Director

How to read Form 4 transaction codes